AB & B Biotech
02627.HKTaizhou, China· Est.
A Chinese vaccine developer advancing proprietary subunit and mRNA vaccines, with a lead quadrivalent influenza vaccine in late-stage trials.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
A Chinese vaccine developer advancing proprietary subunit and mRNA vaccines, with a lead quadrivalent influenza vaccine in late-stage trials.
Infectious Disease
Technology Platform
Proprietary subunit vaccine platform for high-purity antigen production and a developing mRNA vaccine platform.
Opportunities
First-to-market potential in China for a quadrivalent subunit influenza vaccine, and international expansion via the FDA-cleared monkeypox mRNA vaccine trial and the Walvax partnership.
Risk Factors
Regulatory delays in China NDA approval, intense competition from established flu vaccine manufacturers (Sanofi, Seqirus, CSL), and execution risk in scaling mRNA platform development.
Competitive Landscape
Competes with global influenza vaccine leaders (Sanofi, GSK) and domestic Chinese players; differentiates through a proprietary subunit platform claiming higher purity/safety and a dual-path strategy (subunit + mRNA).